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Take home message 
Muscle mitochondrial function is not impaired in age or COPD. Whole-body and 
mitochondrial exercise training adaptations are robust in young, evident in older, and 





COPD patients exhibit lower peak oxygen consumption (  2
PEAK), altered muscle metabolism 
and impaired exercise tolerance compared with age-matched controls. Whether these traits 
reflect muscle level deconditioning (impacted by ventilatory constraints) and/or dysfunction 
in mitochondrial ATP production capacity is debated. By studying aerobic exercise training 
(AET) at a matched relative intensity and subsequent exercise withdrawal period (EW) we 
aimed to elucidate the whole-body and muscle mitochondrial responsiveness of healthy-
young (HY), healthy-older (HO) and COPD volunteers to whole-body exercise.  
 
The HY (n=10), HO (n=10) and COPD (n=20) volunteers were studied before,            -
                 2
PEAK) and after four-weeks EW.   2
PEAK, muscle maximal mitochondrial 
ATP production rates (MAPR), mitochondrial content, mitochondrial DNA copy number and 
abundance of 59 targeted fuel metabolism mRNAs were determined at all time-points. 
 
Muscle MAPR (normalised for mitochondrial content) was not different for any substrate 
combination in HO, HY and COPD at baseline, but mitochondrial DNA copy number relative 
to a nuclear-encoded house-keeping gene was greater in HY (mean+SD) (804+67) than in HO 
(631+69), p=0.041. AET             2
PEAK in HO (17%,p=0.002) and HY (21%,p<0.001) but 
not COPD (p=0.603). Muscle MAPR for palmitate increased with training in HO (57%, 
p=0.041) and HY (56%,p=0.003) and decreased with EW in HO (-45%,p=0.036) and HY (-
30%,p=0.016), but was unchanged in COPD (p=0.594). Mitochondrial DNA copy number 
increased with AET in HY (66%,p=0.001) but not HO (p=0.081) or COPD (p=0.132). The 




Intrinsic mitochondrial function was not impaired by ageing or COPD in the untrained state. 
Whole-body and muscle mitochondrial responses to AET were robust in HY, evident in HO, 
but deficient in COPD. All showed robust muscle mRNA responses. Higher relative exercise 
intensities during whole-body training may be needed to maximise whole-body and muscle 





Compared to age-matched healthy volunteers, patients with COPD exhibit lower whole-body 
maximal oxygen consumption (1-3) and abnormal skeletal muscle metabolic characteristics. 
Altered muscle fibre composition (4, 5); lower fibre cross-sectional area (6) and reduced 
capillarity (7) are apparent in COPD. At a mitochondrial level, lower ATP production capacity 
(reflected by lower maximal activities of mitochondrial enzymes (1)); altered mitochondrial 
efficiency (8); and both lower mitochondrial DNA (mtDNA) copy number and greater 
prevalence of mtDNA deletions (9) have been described in COPD.  Collectively, these 
differences influence muscle metabolic responses to acute exercise, for example greater 
non-mitochondrial ATP production and adenine nucleotide loss (10), accentuating peripheral 
muscle fatigue development and reduced exercise capacity in COPD.  
It is debated to what extent differences in muscle energy metabolism in COPD reflect muscle 
level deconditioning (associated with reduced mitochondrial volume and/or number) and/or 
a disease-specific COPD mitochondropathy (characterised by impaired intrinsic capacity of 
mitochondrial units for respiration or ATP production (8, 9, 11-15)). Similarly, chronological 
ageing has been linked with lower muscle mitochondrial protein content (16) and lower 
mitochondrial intrinsic capacity (17, 18) such that the aetiology of mitochondrial dysfunction 
in COPD could be age and/or disease related. 
Aerobic exercise training robustly increases several markers of muscle mitochondrial content 
and function in young (19) and older (16) volunteers, but whether similar mitochondrial 
responses to aerobic exercise training occur in patients with COPD is uncertain, not least 
because ventilatory limitation in COPD can prevent skeletal muscle from being adequately 
challenged, thereby reducing training adaptation (20, 21). 
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Importantly, as far as we are aware, limited data are available depicting the impact of 
aerobic exercise training on markers of mitochondrial abundance and highly sensitive, direct 
measures of mitochondrial ATP production capacity in relation to whole-body 
cardiorespiratory adaptation in healthy, young and older volunteers and patients with COPD 
training concurrently. Similarly, these responses on return to habitual physical activity 
following training have not been depicted. Such data would provide insight regarding the 
aetiology of mitochondrial decline with age and COPD, and the mechanisms of exercise 
intervention in countering age and COPD related muscle decline and exercise intolerance. 
Such insight would also be beneficial to appreciate the utility of the mitochondrion as a 
therapeutic target.  
We therefore aimed to determine the impact of matched relative intensity aerobic exercise 
training over an 8 week aerobic training regimen at 65% peak oxygen uptake (  2
PEAK) and 
again 4 weeks following exercise withdrawal in healthy young and older volunteers and 
patients with COPD. Outcome measures include whole-body cardiorespiratory responses, 
markers of muscle mitochondrial content, maximal rates of muscle mitochondrial ATP 
production (MAPR), and the expression of mRNAs intimately linked to muscle fuel utilisation. 
We hypothesised that the response of MAPR and   2
PEAK to exercise intervention and 
withdrawal would differ between young and older healthy groups and between older 
healthy and COPD groups due to the impact of advanced age and disease pathology on 





Due to limited article length additional detailed information for all methods is provided in 
the online supplement. 
 
Subjects 
Three groups of sedentary volunteers were recruited; patients with COPD (and significant 
exercise limitation due to breathlessness; MRC Grade >3) aged 60-80 years (COPD), age-
matched healthy older (HO), and healthy younger (HY) subjects aged 18-35 years (inclusion 
criteria are in Table S1).  
 
Study Design 
A prospective, non-randomised interventional cohort study was performed. Anthropometry, 
pulmonary function and quadriceps strength were assessed at baseline and two symptom-
limited incremental (first being a familiarization) and one submaximal cycling 
cardiopulmonary exercise tests (CPET) performed. Seven-day physical activity levels were 
assessed (accelerometry) before a fasted state resting quadriceps muscle biopsy was 
obtained (22). Participants commenced eight-weeks fully supervised cycling aerobic exercise 
training (AET; 3 sessions of 30 minutes per week) at a                               
  2
PEAK. This intensity was chosen to elicit increases in muscle lipid and carbohydrate flux 
(23, 24). Training intensity was reset at week four if workload at   2
PEAK had increased. After 
eight weeks training, participants were instructed to resume their pre-training habitual 
physical activity levels and were followed up after four weeks (week 12). CPET were 
repeated at weeks 4, 8 and 12. Further resting muscle biopsies were performed after eight-
weeks (24 hours after preceding training session) and four weeks post exercise withdrawal 
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(week 12). The study design is outlined in Fig S1 of the online supplement. Ethical approval 
was granted by the NHS National Research Ethics Service and the trial registered at 
https://doi.org/10.1186/ISRCTN10906292. All participants provided written informed 
consent.  
 
Muscle mitochondrial preparation  
Muscle samples were immediately subjected to a homogenisation, centrifugation and 
resuspension protocol and kept on ice immediately prior to quantification of MAPR. 
 
Maximal mitochondrial ATP production rates (intrinsic mitochondrial function)  
MAPR was assessed utilising the bio-luminometric method described by Wibom et al (25). 
Briefly, diluted mitochondrial suspension, ADP, and an ATP monitoring reagent (firefly 
luciferase) were combined with the following substrate combinations: glutamate and 
succinate; glutamate and malate; pyruvate and malate; palmitoyl-l-carnitine and malate; 
succinate; and double-distilled water. All values were normalised to muscle citrate synthase 
activity. 
 
Citrate synthase activity  
Muscle citrate synthase (CS) activity, a robust surrogate marker of mitochondrial content 






Relative mitochondrial DNA copy number  
The abundance of mitochondrial encoded (mtDNA) NADH:ubiquinone oxidoreductase core 
subunit 1 was established using real-time PCR and expressed relative to genomically 
encoded (nDNA) hydroxymethylbilane synthase as previously described (28). 
 
Targeted muscle mRNA expression 
mRNA was extracted from snap-frozen muscle as previously described (29), and quantitative 
real-time PCR performed. The abundance of 59 transcripts involved in muscle fuel 
metabolism was assessed (supplement and Table S2), and Ingenuity Pathway Analysis (IPA; 
QIAGEN, Hilden, Germany) was used to interrogate those differentially regulated. 
 
Statistical analysis 
Data are presented as mean ± SD (baseline) or SEM (change over time). Assumptions of 
normality were assessed using normal probability plots and Shapiro-Wilk testing. Between-
group mean differences at baseline were assessed using one-way ANOVA and within-group 
changes across time were tested using one-way repeated measures ANOVA with post hoc 
Fishers LSD using IBM SPSS Statistics for Windows, version 21 (IBM Corp., Armonk, N.Y., 
USA). A calculation of statistical power can be found in the online supplement. For clarity, 





Baseline subject characteristics are reported in Table 1. Body mass index and fat-free mass 
index were not statistically different between groups at baseline. Whilst all groups were 
non-active, the mean step-count in COPD patients was lower than HO (p=0.046) and below 
the sedentary lifestyle index for adults of 5,000 steps/day (30).   
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Age, years 70.7 
(5.1) 
28.0 (5.1) 70.2 (5.9) <0.001 <0.001 0.834 
Female, 
number   † 


























121.3 (19.1) 0.010 0.667 0.007 
RV/TLC, ratio 38.4 
(4.2) 











Never : Ex  † 
0 : 6 : 4 0 : 10 : 0 0 : 0 : 20 <0.001   
Smoking, 
pack years  ‡ 
18.3 
(21.5) 
(n = 4) 
- 38.5 (15.4) 0.036 - 0.036 
BMI, kg/m2 28.5 
(3.3) 
26.0 (7.6) 29.0 (6.4) 0.430 - - 








98.6 (36.1) 0.021 0.573 0.058 
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0.040 0.879 0.046 
HO, Healthy Older group; HY, Healthy Young group.  Values are mean (SD). FEV1, forced 
expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; TLC, total lung 
capacity; TLCO, transfer factor for the lung of carbon monoxide; BMI, body mass index; 
FFMI, fat-free mass index; QMVC, quadriceps maximum voluntary contraction. Percent 
predicted values are calculated from normal values (31).  †                      bu     




Muscle CS maximal activity (mitochondrial content), MAPR (intrinsic mitochondrial function), 
and mitochondrial DNA copy number at baseline are shown in Table 2. There was no 
statistical difference in CS activity between groups (p=0.070). Muscle mitochondrial DNA 
copy number was less in HO than in HY (p=0.041, Table 2). Intrinsic mitochondrial function 
(MAPR) was not statistically different in HO compared to HY or COPD at baseline for any 




Table 2. Baseline measures of quadriceps mitochondrial content and function 
 
 
During incremental exercise testing at baseline, HY reached a higher workload (p=0.001)     
  2
PEAK (p<0.001) compared to HO           2
PEAK (p=0.026) and peak work rate (p=0.003) 
were less in COPD relative to HO (Table S3). Measures                   2


















CS activity, mmol acetyl CoA. 







0.070 - - 
MAPR (Glutamate and 
Succinate),  
μmol ATP mmol-1 acetyl-CoA 
min-1 
1235 (193) 1249 (142) 1148 
(147) 
0.884 - - 
MAPR (Glutamate and Malate),  
μmol ATP mmol-1 acetyl-CoA 
min-1 
975 (340) 963 (355) 806 (277) 0.269 - - 
MAPR (Pyruvate and Malate),  
μmol ATP mmol-1 acetyl-CoA 
min-1 
658 (245) 570 (161) 477 (195) 0.073 - - 
MAPR (Palmitate),  
μmol ATP mmol-1 acetyl-CoA 
min-1 
488 (169) 447 (86) 429 (169) 0.616 - - 
MAPR (Succinate),  
μmol ATP mmol-1 acetyl-CoA 
min-1 
149 (35) 118 (48) 131 (76) 0.521 - - 
Mitochondrial DNA copy 
number, relative number  
631 (69) 804 (67)  525 (35) <0.001 0.04
1 
0.140 
HO, Healthy Older group; HY, Healthy Young group. Values are mean (SD). CS, citrate synthase; MAPR, 
maximal mitochondrial ATP production rates normalised to CS activity for various mitochondrial 
substrates. Mitochondrial DNA copy numbers expressed relative to nuclear DNA.  
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compared to HO, patients with COPD reached a lower respiratory exchange ratio (RER, 
p<0.001 ,    u   v              , p=0.020) and heart rate (HR, p=0.071), but utilised a 
significantly greater proportion of their predicted maximum voluntary ventilation (MVV, 
p<0.001) (Table S3). Responses to sub-maximal steady-state exercise are shown in Table S4. 
 
Influence of aerobic training and subsequent exercise withdrawal 
Habitual physical activity levels in the 1st (week 9) and 4th (week 12) week of exercise 
withdrawal did not differ from baseline in any group (HO p=0.961, HY p=0.765, COPD 
p=0.686), see Table S5 supplementary file). HO and HY participants increased   2
PEAK by 18% 
(p=0.002) and 21% (p<0.001), respectively, following eight-weeks training (Fig. 1A), but there 
was no change in   2
PEAK in the COPD group (p=0.603). Following four-weeks of exercise 
withdrawal,   2
PEAK remained significantly greater than baseline in HO and HY groups (p 
=0.017 and p=0.004, respectively), whilst   2
PEAK was lower than baseline (p=0.026) and 
week 8 of exercise training (p=0.033) in the COPD group. 
RER during steady-state sub-maximal exercise (at 65% of   2
PEAK at baseline) was reduced in 
all groups after 8-weeks training (within-group change HO p<0.001, HY p<0.001, COPD 
p=0.003, Fig. 1B), and remained less than baseline after 4 weeks exercise withdrawal (HO 
p<0.001, HY p<0.001, and COPD p=0.013). HR during steady-state sub-maximal exercise 
decreased in all groups in the trained state  (HO p=0.002, HY p<0.001, and COPD p=0.003) 
             u                  b    p<0.05) as shown in Fig. S2. 
 
 There was no statistical increase in muscle CS activity in any group with training (HO 
p=0.120, HY p=0.682, COPD p=0.133), but following four weeks of exercise withdrawal CS 
activity in the COPD group was less than baseline (p=0.015) and eight weeks of training 
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(p<0.001), Fig. 2A). Mitochondrial DNA copy number was statistically unchanged from 
baseline by AET and the return to habitual physical activity in HO (p=0.120) and COPD 
(p=0.132) volunteers (Fig. 2B).  By contrast, there was a robust increase in mitochondrial 
DNA copy number with AET in the HY group (p<0.001), which declined on return to habitual 
physical activity (p<0.001), although remaining greater than baseline (p=0.024, Fig. 2B). 
 
Exercise training intervention increased MAPR from baseline in HY volunteers for three 
substrate combinations (palmitate, p=0.003; glutamate and succinate, p=0.008; glutamate 
and malate, p=0.011, Fig. 3), and for palmitate in HO volunteers (p0.041, Fig. 3A), but had no 
robust impact with any substrate combination in COPD (all p>0.05).  Withdrawal of AET 
resulted in the return of MAPR to baseline rates in HY (palmitate, p =0.016; glutamate and 
succinate, p<0.001; glutamate and malate, p=0.003) and HO volunteers (palmitate, p=0.036), 
but MAPR was unchanged from baseline in COPD (all substrates p>0.05) (Fig. 3). There was 
no change in MAPR from baseline for the mitochondrial substrates pyruvate and malate or 
succinate in any group of volunteers (all p>0.05, data not shown). 
 
Based on changes in muscle mRNA expression from baseline, Fig. 4 illustrates that IPA 
identified both muscle lipid and carbohydrate metabolism to be altered following 8 weeks of 
AET and 4 weeks of exercise withdrawal in HO, HY and COPD. The y-axis displays the -log of 
the p-value for each cellular function, which is a measurement of the likelihood that the 
association between a set of focus transcripts and a given function is due to random chance 
with the threshold of significance of the within-group change equivalent to p<0.05. Figure 4 
illustrates that based on the collective change in mRNA abundance the consistency of 
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response of these two cellular functions to exercise training and 4 weeks exercise 
withdrawal was very similar in HO, HY and COPD. 
 
Fig. 5 highlights the changes in mRNA abundance from baseline for individual genes 
identified by IPA to compromise the lipid metabolism function shown in Fig. 4 following 8 
weeks of training. The number of mRNAs and the magnitude and direction of change of each 
was similar when comparing HO, HY and COPD groups.  The same was true of individual 
mRNA expression changes from baseline after 4 weeks exercise withdrawal for the lipid 
metabolism function (Fig. S3). Changes in mRNA abundance following 8 weeks of exercise 
training (Fig. 6) and 4 weeks exercise withdrawal (Fig. S4) for individual genes deemed to 
represent carbohydrate metabolism broadly followed the same magnitude and direction of 
change when comparing HO, HY and COPD groups. 
 
DISCUSSION 
The major novel findings of the present study are, firstly, that intrinsic mitochondrial 
function was not significantly different between HO, HY and COPD at baseline suggesting 
that mitochondrial function was not impaired in the basal state in patients with COPD or 
with healthy ageing. Secondly, changes in whole-body and muscle mitochondrial function in 
response to 8 weeks endurance exercise training at the same relative intensity were robust 
in HY volunteers, less robust in HO volunteers and largely absent in COPD patients. These 
diminished responses could be a consequence of the lower absolute muscle loading 
experienced during training, particularly in COPD where the potential impact of ventilatory 
limitation to exercise training load exists, but the robust muscle transcriptional response to 
exercise intervention across all groups speaks against this, and points to post-transcriptional 
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regulation of muscle adaptation being different during exercise training. Finally, in keeping 
with the observation in HY volunteers (19) four weeks of exercise training withdrawal 
returned intrinsic mitochondrial function to that seen in the baseline state in HY and HO 
volunteers.  
It is debated to what extent changes in muscle energy metabolism in COPD reflect muscle 
level deconditioning and/or a disease-specific COPD mitochondropathy (8, 9, 11-15). Some 
data indicate that muscle mitochondrial respiration (corrected for total mitochondrial 
content) in patients with COPD is not impaired compared with older healthy volunteers (11, 
13), as has been reported in other chronic disease states, e.g. Type 2 diabetes (32).  
Conversely, however, there is evidence that low muscle mitochondrial oxidative capacity in 
COPD cannot be explained by muscle level deconditioning alone and is likely driven by the 
disease pathophysiology, including a shift away from complex I-driven respiration towards 
metabolically less-efficient complex II-driven respiration (8), greater mtDNA deletions, 
increased markers of abnormal fibre specific respiration and suppressed mitochondrial 
proliferation (e.g. mtDNA copy number) (9, 12). Given mitochondrial oxygen utilisation can 
be uncoupled from ATP production in pathophysiological states (33), a definitive conclusion 
as to whether a COPD related mitochondropathy truly exists may be clouded by 
measurement of mitochondrial respiration as a surrogate of ATP generation, (11, 13) a 
question addressed by the current study which utilised a sensitive measure of maximal 
mitochondrial ATP production rates directly. These data in combination with quantification 
of mitochondrial density (CS), and proliferation (mtDNA copy number) accord with the 
evidence that intrinsic mitochondrial function in patients is not impaired with ageing (16) or 
in the presence of  COPD (11, 13). 
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Chronic aerobic exercise training increases several markers of muscle mitochondrial content 
and function in young (19) and older (16) volunteers, but limited information is available as 
to whether similar mitochondrial responses to aerobic exercise training occur in patients 
with COPD, not least because ventilatory limitation in COPD can prevent skeletal muscle 
from being adequately challenged during whole-body exercise, thereby reducing training 
adaptation (20). High-intensity restricted muscle group training has been shown to restore 
mitochondrial function in patients with COPD to that observed in age-matched controls 
(albeit n=5), although it is unknown whether functional capacity also improved (13). Picard 
et al (11), also pointed to muscle deconditioning, rather than mitochondrial dysfunction, 
being the driver of lower maximal rates of mitochondrial respiration in patients with COPD. 
In the present study, exercise training of a large muscle mass was performed at an intensity 
high enough to increase mitochondrial lipid and carbohydrate oxidation yet within the limits 
of tolerance for all groups. This exercise regimen produced robust changes in whole-body 
and muscle mitochondrial function and proliferation in HY volunteers, which were 
diminished in HO volunteers and absent in COPD patients. We acknowledge that muscle-
level loading may have been truncated in the COPD group due to ventilatory limitation 
restricting whole-body exercise tolerance. Importantly, however, following exercise 
intervention the muscle transcriptional response of genes directly linked to muscle lipid and 
carbohydrate use was similar in patients with COPD compared to HO and HY volunteers. 
Furthermore, a decrease in steady-state RER during sub-maximal exercise across the course 
of eight weeks training was evident in all groups demonstrating that chronic exercise 
adaptation in COPD was not limited by fuel mobilisation nor availability during exercise. It 
would appear rather, that the training regimen employed was not sufficient to elicit 
adaptation in post-transcriptional regulation of mitochondrial biogenesis or mitochondrial 
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function, particularly in COPD patients. This may result from ventilatory limitation restricting 
the magnitude of the muscle level challenge, however it has also been proposed that the 
plasticity of skeletal muscle adaptive responses to contractile activity is diminished with age 
and age-related disease, and this extends to mitochondrial proliferation and function, 
suggesting that a greater contractile stimulus is required to attain a similar phenotype 
adaptation (34). Emerging sites for such post-transcriptional limitation include muscle 
translational efficiency (ribosome activity) and translational capacity (ribosome number) 
(35). 
Remarkably   2
PEAK and muscle CS activity in the COPD patients declined below the values 
recorded at baseline and following exercise training intervention, which was not observed in 
HY and HO volunteers. There is no obvious explanation for this observation given habitual 
physical activity levels during the first and fourth week of exercise withdrawal were not 
significantly different to that measured at baseline. However, it should be acknowledged 
that triaxial accelerometery, which was used to quantify step count in the current study, 
cannot quantify the intensity of the activities of daily living and therefore may perhaps 
explain the apparent deconditioning observed in the COPD group following 4 weeks of 
exercise withdrawal. 
This study, through deliberate selection of sedentary healthy volunteers, better matched for 
habitual physical activity status of subjects compared to previous publications comparing 
COPD and health, and furthermore employed a tightly supervised exercise protocol. It is 
acknowledged that the sample size (although large for a study employing a demanding 
intervention and detailed metabolic and physiological measures) limits the generalisability of 
findings to broader populations. The fat-free mass of patients with COPD in this study was 
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normal, further limiting the generalisability of these findings to patients with low fat-free 
mass in whom differences in response to aerobic training (particularly at an mRNA level) 
have previously been observed (36).  Finally, a preferential loss of type I oxidative fibres has 
previously been observed in COPD, leaving a relatively large proportion of type II fibres 
compared to healthy controls (4, 5). Distinct muscle fibre type responses to exercise training 
would have added additional insight, however due to limited tissue availability, it was not 
possible to characterise individual muscle fibre-type responses in this study. A further 
limitation of the current study is that it does not report muscle responses at a protein level 
downstream of changes in muscle mRNA abundance. 
Our data align with the view that in COPD patients where maximal pulmonary ventilation is 
constrained, partitioned training strategies such as interval or restricted muscle group 
training aimed at maximising muscle level training intensity are likely to stimulate greater 
muscle level adaptation (21, 37), and thereby possibly patient benefit. Furthermore, the 
findings lend mechanistic support to current clinical rehabilitation guidelines recommending 
the prescription of high relative whole-body exercise intensities for people with COPD as low 
relative intensities may be insufficient to provoke robust whole-body and muscle level 
adaptation (38). It is important to acknowledge in addition, the broader effects of PR such as 
improvements in confidence, tolerance of breathlessness and mood that may impact on 
other clinical outcome measures that reflect patient benefit (for example field tests of 
exercise performance) regardless of relative exercise intensity. Nonetheless, enhancing 
adaptation at a muscle level has the potential to benefit patients and we suggest novel drug 
therapies targeting mitochondrial function should take account of the preservation of 
transcriptional responses to exercise training in the COPD group. Identifying the post-
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transcriptional locus of impairment is a critical research question to be addressed in the 
development of such therapies.  
In conclusion, intrinsic mitochondrial function was not impaired with ageing or COPD. 
However, the magnitude of changes in whole-body responses to exercise, rates of 
mitochondrial ATP production and mitochondrial proliferation in response to chronic aerobic 
exercise training were variably blunted with age and further blunted in COPD, possibly as a 
result of ventilatory limitation. The similarity in muscle mRNA responses directly linked to fat 
and carbohydrate oxidation across HY, HO and COPD patient groups points to the plasticity 
of skeletal muscle to exercise induced stress being diminished at the post-transcriptional 
level in COPD. Our findings are relevant to exercise prescription during pulmonary 
rehabilitation, suggesting that higher relative work intensities during whole body aerobic 
training may be needed to stimulate adaptation at a muscle level in COPD and thereby 
maximise patient benefit. 
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Figure 1. a) Within-group change in   2
PEAK normalised for lean body mass expressed as 
percent change from baseline after 8 weeks training, and after a subsequent 4 weeks 
exercise withdrawal where subjects returned to habitual physical activity levels for HO (grey 
squares),  HY (black triangle) and COPD (open circle) groups. b) Respiratory exchange ratio 
(RER) during steady-state sub-maximal exercise at the same time points as above (a). Within 









Figure 2. a) Muscle citrate synthase (CS) activity (mmol acetyl CoA min-1.l mitochondrial 
suspension-1); and b) mitochondrial DNA copy number (relative to nuclear DNA copy 
number) at baseline (open squares), after 8 weeks training (grey squares), and after 4 weeks 
exercise withdrawal (black squares) where subjects returned to habitual physical activity 








Figure 3. Muscle intrinsic mitochondrial function assessed by determining maximal 
mitochondrial ATP production rates (MAPR, μ      P     -1 acetyl-CoA min-1) at baseline 
(open squares), after 8 weeks training (grey squares), and after 4 weeks exercise withdrawal 
(black squares) where subjects returned to habitual physical activity levels. a) palmitoyl-L-
carnitine (Palmitate); b) glutamate and succinate (GS); c) glutamate and malate (GM). Values 






Figure 4. Muscle cellular functions identified by IPA as being altered from baseline after 8 
weeks training (grey squares), and after 4 weeks exercise withdrawal (black squares; where 
subjects returned to habitual physical activity levels) based on mRNA expression data 
generated using quantitative RT-PCR. Lipid metabolism (a) and carbohydrate metabolism (b) 
were significantly influenced after both training and exercise withdrawal. The y-axis displays 
the –log of the p value. The –log of the p v  u          u      by F     ’s exact test right-
34 
 
tailed. Dashed line denotes threshold of statistical significance for within-group change 






Figure 5. Differentially regulated muscle mRNAs associated with lipid metabolism following 8 
weeks training compared to baseline in healthy older, healthy young and COPD groups. 






Figure 6. Differentially regulated muscle mRNAs associated with carbohydrate metabolism 
following 8 weeks training compared to baseline in healthy older, healthy young and COPD 
groups. Abbreviated gene names are defined in Table S2 of the online supplement. 
Online Data Supplement 
Whole-body & muscle responses to aerobic exercise training and withdrawal in ageing & 
COPD 
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Participants for all groups were identified from existing research databases; patients with 
COPD were recruited from outpatient clinics; and the healthy volunteers were identified via 
local advertisement. Participants were not engaged in regular exercise training prior to 
enrollment (<150 min moderate intensity exercise / week and patients had not attended 
pulmonary rehabilitation in preceding 12 months). Inclusion and exclusion criteria are in 
Table S1. 
Table S1. Participant inclusion / exclusion criteria. 




Age >18 & <35  
Not engaged in regular exercise 
programme 
Exceeding 150 min / week 
moderate intensity exercise 
Normal lung function: FEV1 >80% 
predicted, FEV1 / FVC >70% 





Age >60 & <80  
Not engaged in regular exercise 
programme 
Exceeding 150 min / week 
moderate intensity exercise 
Normal lung function: FEV1 >80% 
predicted, FEV1 / FVC >70% 
Any respiratory diagnosis 
COPD Age >60 & <80  
Clinical diagnosis of COPD and 
obstructive spirometry: FEV1 
<80% predicted, FEV1 / FVC 
<70% 
 
Not engaged in regular exercise 
programme 
Attended PR within last 12 months 
MRC grade >3  
Clinically stable Exacerbation within last 4 weeks 
All Groups Ability to give informed consent Any medical condition associated 
with metabolic disturbance (e.g. 
type II diabetes), inflammation 
(e.g. rheumatoid arthritis, 
inflammatory bowel disease), 
impaired muscle function or one 
which affects the ability to perform 
exercise testing and training (e.g. 
cardiovascular disease, significant 
osteoarthritis) 
 Receiving systemic corticosteroid 
medication 
 Receiving anticoagulation therapy 
or condition causing impaired 
clotting / platelet dysfunction 
 Current smoker (ex-smokers < 1 






Figure S1. Study protocol followed by all volunteers. Biopsy, microbiopsy of vastus lateralis; 
CPETIncremental, symptom-limited incremental cardiopulmonary exercise test; CPETSubmax  
                                                                               
              2
PEAK in baseline CPETIncremental; PFT, pulmonary function test; strength, 
quadriceps maximal voluntary contraction; PA, physical activity monitoring for 7 days. 
Training intensity was reset at week four if workload at   2
PEAK had increased. 
 
Baseline assessments 
Baseline assessments were performed over three visits. At visit 1 measures of 
anthropometry (height, body mass, body composition by DEXA), pulmonary function and 
quadriceps strength were performed as was a familiarisation symptom-limited incremental 
cycling cardiopulmonary exercise test (incremental CPET). At the second visit (minimum 48 





















































performed followed by a submaximal cycling exercise tests (separated by >30 minutes 
resting time). A minimum of 7 days later, at the third visit, a quadriceps muscle biopsy was 
performed (week 0). Habitual physical activity was assessed over seven days prior to 
intervention and repeated during the first and last weeks of the exercise withdrawal period. 
Anthropometry, pulmonary function, quadriceps strength and physical activity monitoring 
Measurements of pulmonary function including lung volumes by plethysmography [S1], 
body mass index (BMI), body composition (dual energy x-ray absorptiometry, DEXA; Lunar 
Prodigy, GE Healthcare, Buckinghamshire, United Kingdom), and quadriceps isometric 
strength at 90° knee and hip flexion (Cybex II Norm: CSMi, Stoughton, USA) were performed 
at baseline. Habitual physical activity was monitored using a triaxial accelerometer 
(SenseWear; BodyMedia, Pittsburgh, USA) worn during waking hours on 7 consecutive days 
before baseline, and during the first (week 9) and final (week 12) week of exercise 
withdrawal. A minimum of 8 hours of data per day was required to be included in the 
analysis. The mean step count of the initial 8 hours after waking was calculated for each 
individual. 
Incremental CPET and a submaximal cycling exercise tests 
Incremental CPET was performed in accordance with international guidelines [S2] on an 
electromagnetically braked cycle ergometer (Lode Corival, Groningen, Netherlands) with 
continuous electrocardiogram, oxygen saturation and blood pressure monitoring. After 
three min unloading pedalling, workload was increased progressively (ramp pro            
                                                              –                      
                                                                                        
                                       2     2                       were monitored 
using a metabolic cart (Ergocard Professional, Medisoft, Sorinnes, Belgium) and reported as 
fifteen breath rolling averages. Predicted maximum voluntary ventilation (MVV) was 
calculated as FEV1 X 37.5 (S3). 
Sub-maximal testing was performed                                                     
  2
PEAK achieved in either of the baseline tests and was not changed for subsequent tests. 
Continuous monitoring of cardiorespiratory variables was performed throughout the test 
and an average reported for the steady-state period. The steady-state period excluded the 
first three minutes at test workload and isotime measures were calculated for each 
individual, the duration of which was determined by the shortest test performed by that 
individual (normall                             -                                  
                                                    -                                        
                                                                                        
indicate the physiological stress experienced during training. 
 
Muscle sampling and processing 
Muscle biopsy samples were obtained from the vastus lateralis muscle of the dominant leg 
at mid-thigh level using a needle micro-biopsy technique [S4]. Briefly, after the skin was 
sterilised with Betadine solution, local anaesthetic (lignocaine) was injected subcutaneously 
and to the depth of the fascia. A small incision (5 mm) was made in the skin and any 
subcutaneous adipose, through which a 12 g micro-biopsy needle was inserted (Bard 
Magnum, Arizona, USA). Four passes were performed, each harvesting ~20 mg of tissue. 
Approximately 40 mg of freshly isolated vastus lateralis muscle tissue was finely diced on a 
cooled glass plate, and weighed for mitochondrial function and content measurements. The 
remaining muscle tissue was immediately dissected free of visible adipose and connective 
tissue, snap frozen and stored in liquid nitrogen for subsequent DNA and mRNA analyses. 
The biopsy site was dressed with a butterfly closure, waterproof sterile dressing and a 
compression bandage to apply light pressure in order to minimise the risk of bleeding or 
bruising. Subsequent biopsies were performed 2.5 cm from the preceding incision site. 
Muscle Mitochondrial measurements  
Each sample was homogenised on ice for 3 min in a buffer solution (pH 7.0, KCl 100mM, 
KH2PO4 50 mM, Tris 50 mM, MgCl2 5mM, EDTA 1 mM, ATP 1.8 mM) using a Teflon pestle 
homogeniser. The crude homogenate was then centrifuged at 650 g for 3 min at 4oC, and 
the resultant supernatant was transferred to a test tube and centrifuged at 15,000 g for 3 
min at 4oC. The resulting pellet formed contained the mitochondria. Following this, the 
                                                                               μ  of the 
original homogenisation buffer. This was then centrifuged at 15,000 g for 3 min at 4oC. After 
removal of the supernatant, the pellet was re-suspended in a re-suspension solution (pH 
7.0, human serum albumin 0.5 mg/ml, sucrose 240 mM, monopotassium phosphate 15 mM, 
magnesium acetate tetrahydrate 2mM, EDTA 0.5 mM). The differential centrifugation 
isolated mitochondrial suspension was then kept on ice immediately prior to measurement 
of mitochondrial ATP production rates (MAPR).  
Mitochondrial ATP production rates (intrinsic mitochondrial function) 
Following the method of Wibom et al [S5], 2.5 µl of diluted mitochondrial suspension was 
added to each well of a luminometer plate. The wells contained 200 µl ATP monitoring 
reagent (Firefly Luciferase, 357 µM D-luciferine, 14.3 µM L-luciferine, 15 mM BSA, 1 µM 
Sodium Pyrophosphate Decahydrate, 187.55 mM Sucrose, 18.8 mM monopotassium 
phosphate, 2.5 mM magnesium acetate tetrahydrate, 677 µM EDTA (K Salt) pH 7.0), 12.5 µl 
of 12 mM ADP and 35 µl of the following substrate combinations in duplicate: Glutamate 
(16.4 mM) and Succinate (15 mM); Glutamate (32.75 mM) and Malate (22 mM); Pyruvate 
(50 mM) and Malate (22 mM); Palmitoyl-l-carnitine (5 µM) and Malate (1.5 mM); Succinate 
(2.5 mM); and double-distilled water (ddH2O). A blank that contained all the above 
components except the substrate was run in parallel for each sample. Luminescence was 
continuously recorded for 10 min (BMG LABTECH, Ortenberg, Germany) and an injection of 
150 pM ATP standard took place after 4.6 min. The change in luminescence elicited by the 
ATP standard was used to calculate MAPR. Mitochondrial suspensions were frozen at -80°C 
for subsequent determination of citrate synthase activity (see below). MAPR values were 
corrected for maximal citrate synthase activity (routinely used as an index of mitochondrial 
content / mass) to provide measures of intrinsic mitochondrial function normalised to the 
mitochondrial content of the suspension. 
Citrate synthase activity (mitochondrial content)   
Muscle citrate synthase (CS) maximal activity was determined at 37°C on the isolated 
mitochondrial solution using a kinetic spectrophotometric method to follow the change in 
absorbance of a 5,5'-dithiobis (2-nitrobenzoic acid)(DNTB) buffered solution as previously 
described (E6).             μ                                           μ                 
buffer (95% extraction buffer containing 1% triton) and was homogenised using a glass 
pestle at 200 rpm for 2 min (5). The homogenate was centrifuged at 24,000 g (Eppendorf, 
Hamburg, Germany) before CS was determined spectrophotometrically in the supernatant 
[S5]. Acetyl-CoA is formed at a rate determined by the quantity of CS protein present. 
Relative mitochondrial DNA copy number Genomic DNA (nDNA) and mitochondrial DNA 
(mtDNA) were extracted from skeletal muscle Qiagen using a QIAamp® DNA Mini kit 
                             ’                                                initial tissue 
lysis in a buffer containing proteinase K, incubation for 3 hrs at 56°C to digest the myofibril 
proteins followed by the spinning of the lysates on silica-membrane-based nucleic acid 
purification columns and elution of the mtDNA and nDNA with appropriate buffers. Before 
                        L  Q        4 µL         DN          ty RNase A stock solution 
7    U  L                                  DNA quality and quantity was assessed by 
measurement of light at 260, 280 and 230 nm (Nanodrop One Spectrophotometer, 
Thermoscientific, Waltham, MA, USA). The expression level of hydroxymethylbilane 
synthase (HMBS; nDNA) and encoded NADH:ubiquinone oxidoreductase core subunit 1 
(ND1; mtDNA) was used to evaluate the relative abundance of nuclear and mitochondrial 
DNA and was quantified using TaqMan probe real-time PCR. The TaqMan probe design for 
the detection of nDNA levels was based on interrogation of the intron sequence spanning 
between exons 3-4 of the genomic hydroxymethylbilane synthase (HMBS) gene to avoid any 
mRNA amplification, if present. The probe design for detection of mtDNA levels was based 
on interrogation of a stable fragment of the mtDNA loop, namely the mitochondrially 
encoded NADH:ubiquinone oxidoreductase core subunit 1 (ND1). The 2-Δ                  Δ 
= CtND1-CtHMBS, was used to express the relative number of mtDNA copies. 
Muscle mRNA expression linked to fuel metabolism  
RNA was extracted from ~30 mg snap-frozen muscle as previously described [S7]. First 
strand cDNA was synthesised from 1 µg of total RNA, using Superscript III reverse 
transcriptase (Invitrogen Ltd, Paisley, UK) and random primers (Promega, Southampton, UK) 
and stored at -80oC until analysis.   TaqMan low density arrays were performed using an ABI 
PRISM 7900HT sequence detection system, and data analysed using SDS 2.1 software 
(Applied Biosystems, USA). Data were further analysed using RQ Manager software (Applied 
Biosystems, USA), where the threshold level was normalised across all plates before Ct 
values were calculated for each gene target and sample.  Relative quantification of mRNAs 
of interest was measured using the 2-ΔΔCt method with hydroxymethylbilane synthase 
(HMBS) as the endogenous control as it was unaffected by exercise intervention (data not 
shown). A total of 59 transcripts known to be involved in muscle carbohydrate and lipid 
metabolism were targeted for analysis in the present study (Table S1).  Target selection was 
led by published data involving high-throughput and targeted RT-PCR approaches from our 
research group which identified muscle transcripts responsive to exercise intervention [S8], 
insulin resistance [S9] and changes in fuel metabolism with nutritional [S10] and 
pharmacological intervention [S11]. Additionally unpublished muscle transcript data from 
our group from research involving limb immobilisation in healthy volunteers was accessed. 
To associate altered biological functions to the targeted probe sets, Ct values were 
uploaded to Ingenuity Pathway Analysis (IPA) software (QIAGEN, Hilden, Germany) for 
pathway analysis of gene expression data. The overall outcome of IPA (e.g. cellular function) 
is predicted by calculating a regulation Z-score and an overlap p-value, which are based on: 
                                       ’         ; 2, the magnitude of expression change; 
3, the direction of expression change; and 4, their concordance with the IPA database, 
which is constructed from an extensive curated literature database.  The overlap p-value 
was calculated by IPA to identify significantly enriched function pathways from the 
submitted list of significantly changed genes. These p-values were generated from the right-
tailed Fisher's Exact Test, and a significance threshold of p<0.05 was used to assess the 
statistical significance of the function pathways. In order to control for any enrichment of 
false positive results when undertaking multiple comparisons (type II errors) IPA utilises 
Bonferroni's corrected p-value set at p< 0.05. 
 
Table S2. mRNA transcripts with functions relating to muscle fuel metabolism that were 
quantified in this analysis. 
Abbreviation Gene name ABI ID 
ALDH2 
Aldehyde dehydrogenase 























HK1 hexokinase 1 Hs00175976_m1 














PGM1 phosphoglucomutase 1 Hs01071897_m1 





ACOT1 acyl-CoA thioesterase 1 Hs04195130_s1  
ADIPOQ adiponectin Hs00605917_m1 
APOA1 Apolipoprotein A-I Hs00163641_m1 
APOC1 Apolipoprotein C Hs00155790_m1  
CCL19 















initiation factor 4E 
binding protein 1 
Hs00607050_m1 
FAXDC2 
fatty acid hydroxylase 
domain containing 2 
Hs00260753_m1 
FOXO1 Forkhead box protein O1 Hs01054576_m1 
HSPA14 












insulin-like growth factor 
binding protein 4 
Hs01057900_m1 
IGFBP7 
insulin-like growth factor 
binding protein 7 
Hs00266026_m1 
IL6 
interleukin 6 (interferon, 
beta 2) 
Hs00985639_m1 








protein type 2 
Hs01106565_m1 
ME2 





nuclear factor, erythroid 
2 like 2 Hs00975961_g1 
NRF1 nuclear respiratory factor Hs00192316_m1 
1 
PLA2 Phospholipase A2 Hs00179898_m1 
PLD4 

































transcription factor A, 
mitochondrial 
Hs00273372_s1 
TLR4 toll-like receptor 4 Hs00152939_m1 
TP53 (p53) tumor protein p53 Hs01034249_m1  
UCP2 




















insulin-like growth factor 
1 (somatomedin C) 
Hs01547656_m1 
INSR Insulin receptor Hs00961554_m1 
IRS1 
Insulin receptor substrate 
1 
Hs00178563_m1 
MSTN myostatin Hs00976237_m1 
PDK2 
pyruvate dehydrogenase 




kinase, isozyme 4 
Hs01037712_m1 




Exercise training intervention 
Participant underwent supervised training on an electrically braked cycle ergometer (Lode 
Corival, Groningen, The Netherlands). Three supervised sessions of 30 min duration were 
performed per week. Individuals who were unable to compete 30 min continuously were 
permitted to rest (~5 min) before resuming the session over a total permissible duration of 
60 min. Exercise at the prescribed intensity (                                2
PEAK) is 
known to increase muscle lactate accumulation, pyruvate dehydrogenase complex (PDC) 
activation and flux [S12], and rates of mitochondrial carbohydrate and lipid oxidation from 
both plasma and muscle sources [S13] well above the resting state, thereby providing a 
robust stimulus to muscle metabolic adaptation. 
Statistical analysis 
A power calculation performed on MAPR data (glutamate and succinate) using G-Power 
software (version 3.1.9.2, Dusseldorf University, Germany) for ANOVA one-way fixed effects 
g     α =                        =          =   9              z  =                         
Barany et al. [S14] recommended n=9 for the healthy control group, which we rounded up 
to n=10 for healthy volunteers. Given the inherently variable nature of physiological 
responses in patients with COPD, this number was increased to n=20 in the COPD group. 
 
Approvals & clinical trial registration 
The trail was approved by NHS National Research Ethics Service, West Midlands Committee 
– Coventry & Warwickshire (reference 13/WM/0075) and registered with the UK Clinical 
Research Network (UK CRN) ID: 14080. This trial was registered with www.isrctn.com, 
reference 10906292.  
RESULTS 
Baseline 
Fourteen HO and 15 HY volunteers consented to participate with 10 from each group 
completing all study measures. Twenty-seven patients with COPD consented, 20 of whom 
completed the training intervention and week eight assessments with one drop-out during 
the exercise withdrawal period leaving 19 COPD patients in the week 12 analysis.  
 
Table S3.                                2













PEAK, ml.kg lean mass-
1 min-1 
29.7 (4.0) 44.7 (5.6)** 24.0 (7.4)* 
Work load, W 113.0 (26.4) 167.0 (43.6)** 71.1 (32.5)** 
RER 1.20 (0.09) 1.23 (0.10) 1.05 (0.09)** 
    L min-1 62.8 (16.4) 82.9 (25.5)* 44.9 (16.6)* 
        % 65.4 (15.9) 65.2 (17.0) 103.4 (23.8)** 
 HR % Predicted Max, % 94.4 (10.2) 97.0 (4.8) 85.8 (11.2)* 
                               ;                      ;                     
voluntary ventilation; HR, heart rate predicted maximun = 220 – age (years). Values 
are mean (SD). *, p < 0.05 vs HO; **, p < 0.05 vs HO.  
Table S4                                            -         -                           




There were no significant within-group changes over time in physical activity assessed by 
daily step count (Table S5). 
 
Table S5. Daily step count. 





























Physical activity (daily step count) at baseline (pre-training) and in the 1st and 4th week of 








Work load, W 76 (18) 110 (26)** 46 (21)** 
RER 1.04 (0.34) 1.07 (0.37) 0.98 (0.53)** 
    L min-1 52.2 (11.4) 66.3 (16.9)* 35.7 (11.6)** 
        % 53.8 (11.9) 53.4 (15.9) 83.6 (18.8)** 
HR % Predicted Max, % 86.8 (11.9) 92.6 (3.9) 79.6 (12.1) 
Data represent the steady-state period of a cycling exercise test at an individually 
prescribed work rate (65% of the work rate that corresponded with baseline  
  2
PEAK                                  ;                      ;               
maximum voluntary ventilation; HR, heart rate predicted maximun = 220 – age 
(years).  Values are mean (SD). *, p < 0.05 vs HO; **, p < 0.01 vs HO. 
the exercise withdrawal period. Data are mean (SD).  
 
Heart rate during steady state exercise was reduced from baseline after eight weeks training 
and after four weeks exercise withdrawal in all groups (Fig. S2 A; all p <                  
reduced at the same time points in HO (p < 0.01) and HY (p < 0.05) but was unchanged in 
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Figure S2.                                  -         -                                
                        2
PEAK in the baseline test. A, Change in heart rate (HR) after 8 
weeks training, and after 4 weeks exercise withdrawal where subjects returned to habitual 
physical activity levels. B, Respiratory exchange ratio (RER) at the same time points as above 
(A). Within group change p <         : H   *; HY  †;    D  ‡                  S     
  
 
Figure S3. Differentially regulated muscle mRNAs associated with lipid metabolism following 
4 weeks exercise withdrawal compared to baseline in healthy older, healthy young and 
COPD groups. Abbreviated gene names are defined in Table S2. 
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Figure S4. Differentially regulated muscle mRNAs associated with carbohydrate metabolism 
following 4 weeks exercise withdrawal compared to baseline in healthy older, healthy young 
and COPD groups. Abbreviated gene names are defined in Table S2.  
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